Novartis Aims To Leap-Frog Into Next Immuno-Oncology Wave With Aduro

Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.